null

null

null

null

0.00x Total Debt / Equity (Conservative)

Low direct sensitivity; debt-free clinical-stage biotech funded by equity; 20bp rate shift marginally affects cash runway via money-market yields on ~$150M cash reserves

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API synthesis from Chinese CROs/CMOs; 2) Taiwanese/Indian active pharmaceutical ingredient manufacturers for HBV/HDV antiviral compounds

Negligible currency devaluation exposure; no commercial revenue yet; operations USD-denominated; clinical trial costs in ex-US markets create minor FX exposure

Primarily US-based clinical-stage company; EU and Asia-Pacific clinical trial sites create minor EUR/CNY/AUD exposure; no commercial international revenue

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on specialized CROs (e.g., Covance/LabCorp, Charles River) for IND-enabling studies; single CMO relationships for clinical drug supply represent >30% operational input

Clinical-stage biopharmaceutical; R&D-driven; revenue from partnership/licensing milestones; no commercial product sales; cloud disruption would cause minor operational friction only

Collaboration and licensing agreements (e.g., Gilead partnership history); milestone and royalty model upon commercialization; secondary to grant/equity financing

Low API coupling risk; uses standard scientific software (Dotmatics, Benchling); no proprietary API lock-in; CRO switching costs moderate due to study continuity requirements

Low Howey risk; equity shares in a registered biopharmaceutical company; revenue model is milestone/royalty-based, not investment-contract-like; standard SEC-registered securities

Very High

Moderate GDPR exposure via EU clinical trial patient data; CCPA exposure limited; clinical data governed by ICH-GCP and EMA regulations; requires DPAs with EU CROs

Low antitrust risk; small-cap clinical-stage company with no market dominance; HBV/HDV drug pipeline competes in fragmented emerging market with Gilead, Roche

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% non-recurring; revenue episodic from partnership milestones and collaboration agreements; no subscription or retainer revenue stream currently

Milestone payments, upfront licensing fees, and future royalties on net sales; dependent on clinical success and partnership deal terms

No commercial pricing yet; future HBV/HDV drug pricing will benchmark against Gilead's Vemlidy (~$15K/year); curative-intent premium pricing likely if functional cure achieved

Potentially high if functional HBV cure demonstrated; payer willingness-to-pay modeled at $50K-$80K one-time curative therapy; current rating speculative pending Phase 2 data

Projected 80-90% gross margin at commercialization typical for biotech royalty/drug sales; current gross margin not meaningful given pre-revenue stage

No free-rider leakage problem applicable; proprietary IP-protected compounds; no platform or open-access model; pipeline exclusivity maintained via patents

Sublinear growth model; clinical success drives milestone revenue without proportional headcount increases; ~60-80 employees; commercialization would require BD and medical affairs hiring

Near-zero marginal cost of incremental licensing revenue; clinical trial scale-up costs are primary growth expense; CMO manufacturing scale reduces per-unit cost significantly

Not applicable; Assembly Biosciences is not a franchise business model

At 10x scale (post-commercialization), CAC becomes payer/hospital contracting cost; physician detailing force ~200-300 reps estimated for HBV market; CAC payback <1 year for curative therapy

No meaningful network effects; drug efficacy independent of user base; scientific data network effects marginal via clinical trial insights; not a platform business

-2.4% Return on Assets (Negative equity)

Moderate-high recession resistance; HBV/HDV treatments address chronic unmet medical need; patient demand inelastic; funding risk exists if equity markets tighten for biotech

Biopharmaceutical licensing partners (e.g., large pharma) as primary revenue customers; high concentration risk with limited partnership counterparties

End-market patients with chronic HBV/HDV infection (~300M HBV globally); payers (commercial insurers, Medicare, international health systems) as secondary revenue gatekeepers

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.1% CapEx / Revenue (Low-CapEx Asset-Light)

0001426800

ASMB